Arvinas (ARVN) Cash from Financing Activities (2017 - 2026)
Arvinas (ARVN) posted quarterly Cash from Financing Activities of -$100000.0 for Q1 2026, little changed year-over-year from -$100000.0 in Q1 2025, and up 99.86% quarter-over-quarter from -$74.0 million in Q4 2025.
Powered by 
Analysis
Arvinas (ARVN) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Arvinas' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$100000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed 0.0% year-over-year to -$100000.0; the TTM figure through Mar 2026 stood at -$91.4 million (down 1574.19% YoY), while the FY2025 annual figure was -$91.4 million, down 1256.96% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$100000.0, up from -$74.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $334.8 million in Q4 2023, with the low at -$74.0 million in Q4 2025.
- The 5-year median for Cash from Financing Activities is $500000.0 (2022), against an average of $17.4 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 66860.0% in 2023, then plunged 14900.0% in 2025.
- Arvinas' Cash from Financing Activities stood at $500000.0 in 2022, then surged by 66860.0% to $334.8 million in 2023, then sank by 99.85% to $500000.0 in 2024, then slumped by 14900.0% to -$74.0 million in 2025, then jumped by 99.86% to -$100000.0 in 2026.
- Business Quant data shows ARVN's Cash from Financing Activities at -$100000.0 in Q1 2026, -$74.0 million in Q4 2025, and -$17.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Arvinas | 609.44 Mn | 41.54 Mn | - | 400,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | -74.00 Mn |
| Sep 30, 2025 | -17.80 Mn |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 334.80 Mn |
| Sep 30, 2023 | 37.90 Mn |
| Jun 30, 2023 | 500,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 3.90 Mn |
| Sep 30, 2021 | 266.60 Mn |